A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

NCT00988624 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Huntington Disease

Interventions

DRUG: Dimebon IR Tablet
DRUG: Dimebon MR1
DRUG: Dimebon MR2
DRUG: Dimebon MR3
DRUG: Dimebon MR4

Sponsor

Pfizer

Collaborators

[object Object]